2024
Randomized Clinical Trials That Advance Health and Health Equity
Wang T, Corbie G, Allore H, Anderson T, Durant R, Ganguli I, Grady D, Gross C, Katz M, Mody L, Tripodis Y, Inouye S. Randomized Clinical Trials That Advance Health and Health Equity. JAMA Internal Medicine 2024, 184 PMID: 39008289, DOI: 10.1001/jamainternmed.2024.3149.Peer-Reviewed Original ResearchTracking Physical Activity One Step at a Time
Gross C, Durant R. Tracking Physical Activity One Step at a Time. JAMA Internal Medicine 2024, 184: 726-726. PMID: 38767900, DOI: 10.1001/jamainternmed.2024.0898.Peer-Reviewed Original ResearchSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioChanges in Facility Share of Medicaid-Insured Patients with Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act
Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-Insured Patients with Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024 PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.Peer-Reviewed Original ResearchFacility-level changesAffordable Care ActNon-expansion statesUrological cancer patientsProportion of patientsExpansion statesBaseline proportion of patientsUrologic cancer careHigh-income zip codesCancer patientsFactors associated with changesPre-post designCancer care centerPost-ACA periodMedicaid expansion statesMultivariate logistic regressionMedicaid-insured patientsCancer careUrological cancersZip codesCare ActMedicaid patientsMedicaidLogistic regressionCare centerProgress in Lung Cancer Screening Adoption
Richman I, Gross C. Progress in Lung Cancer Screening Adoption. JAMA Internal Medicine 2024, 184 PMID: 38857025, DOI: 10.1001/jamainternmed.2024.1673.Peer-Reviewed Original ResearchMaking Drug Approval Decisions in the Face of Uncertainty: Cumulative Evidence versus Value of Information
Dijk S, Krijkamp E, Kunst N, Labrecque J, Gross C, Pandit A, Lu C, Visser L, Wong J, Hunink M. Making Drug Approval Decisions in the Face of Uncertainty: Cumulative Evidence versus Value of Information. Medical Decision Making 2024, 44: 512-528. PMID: 38828516, PMCID: PMC11283736, DOI: 10.1177/0272989x241255047.Peer-Reviewed Original ResearchValue-of-informationVOI approachPolicy decisionsValue-of-information analysisSuboptimal resource useEvidence accumulationVOI resultsAdministrative policy decisionsDecision making resultsDecision-making strategiesApproval decisionsPolicy approachesMeta-analysisResearch settingsResource useHealth technology assessmentCrisis responseCase studyPolicyCumulative evidenceResource allocationComplexity of decisionsResearch prioritizationDecisionHealth outcomesCharacterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 1-10. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factorsIntegrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study.
Thanarajasingam G, Dueck A, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Paludo J, Power B, Ross J, Ruddy K, Schellhorn S, Tarver M, Wood W, Gross C, Kluetz P. Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study. Journal Of Clinical Oncology 2024, 42: 1564-1564. DOI: 10.1200/jco.2024.42.16_suppl.1564.Peer-Reviewed Original ResearchPhysical functionPF measuresDaily stepsClinically meaningful change scoresAverage daily stepsEvaluate physical functionDigital health studiesMeasures of PFWearable dataHealth StudyWalk testWeekend daysCore outcomeChange scoresPerformance statusTreatment toleranceDetect changesPearson correlationECOG performance statusBreast cancerEvaluate feasibilityCancer trialsSignificant declineData collectionBaselineOutcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian ageOpioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.Peer-Reviewed Original ResearchDocumented painHealth systemOpioid prescribingOpioid prescriptionsOpioid prescribing trendsYale New Haven Health SystemPrescribing trendsMetastatic cancerDocumented pain scoresUS health systemOpioid usePain scoresAdult patientsCalculated predicted probabilitiesFlowsheet dataRetrospective cohort studyRelated harmSolid tumor malignanciesCohort studyCancer painPrescribingContext of cancer treatmentStudy criteriaPainSurgery cohortPersonalized risk assessment of new onset depression in long-term cancer survivors.
Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.Peer-Reviewed Original ResearchHistory of depressionIncidence of depressionCumulative incidence of depressionRisk of developing depressionLong-term survivorsPredictors of depressionCancer survivorsDisease specific factorsCumulative incidenceNon-HispanicHigher risk of developing depressionRectal cancerLong-term cancer survivorsBreast cancer survivorsCensus tract povertyColon cancerEpisodes of bipolar I disorderPrevalence of depressionMean survival time modelsDiagnosis of depressionReceipt of treatmentAssociated with prior historyHormone receptor statusPatients aged <Adjuvant endocrine therapyImproving Women’s Health Across the Life Span—JAMA Internal Medicine Call for Papers
Grady D, Allore H, Corbie G, Covinsky K, Durant R, Ganguli I, Gross C, Katz M, Mody L, Wang T, Tripodis Y, Inouye S. Improving Women’s Health Across the Life Span—JAMA Internal Medicine Call for Papers. JAMA Internal Medicine 2024, 184: 472-473. PMID: 38497973, PMCID: PMC11184509, DOI: 10.1001/jamainternmed.2024.0136.Peer-Reviewed Original ResearchPhysicians in Private Equity Practices—Canaries in a Coal Mine?
Gross C, Corbie G. Physicians in Private Equity Practices—Canaries in a Coal Mine? JAMA Internal Medicine 2024, 184: 580-581. PMID: 38466292, DOI: 10.1001/jamainternmed.2024.0069.Peer-Reviewed Original ResearchPD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchPD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.Peer-Reviewed Original ResearchCancer and incarceration: a call for action
Richman I, Gross C, Wang E. Cancer and incarceration: a call for action. The Lancet Oncology 2024, 25: 530-531. PMID: 38697151, DOI: 10.1016/s1470-2045(24)00201-8.Peer-Reviewed Original ResearchFunctional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study
Sedrak M, Sun C, Bae M, Freedman R, Magnuson A, O’Connor T, Moy B, Wildes T, Klepin H, Chapman A, Tew W, Dotan E, Fenton M, Kim H, Katheria V, Muss H, Cohen H, Gross C, Ji J. Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study. Journal Of Cancer Survivorship 2024, 1-13. PMID: 38678525, DOI: 10.1007/s11764-024-01594-3.Peer-Reviewed Original ResearchEarly-stage breast cancerPF-10 scorePF-10Physical functionNon-cancer controlsFunctional declineBC controlOlder breast cancer survivorsRAND 36-Item Short FormBreast cancerCohort of older adultsOlder womenBreast cancer survivorsImprove health outcomesPhysical function subscalePhysical function declineAccelerated functional declineBreast Cancer StudyCancer survivorsFunction subscaleHealth outcomesGroup of womenOlder adultsControl groupShort formImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate